Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies

P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies Many P-glycoprotein (P-gp) inhibitors studied in vitro and in vivo are also known or suspected to be substrates and/or inhibitors of cytochrome P-450 3A (CYP3A). Such overlap raises the question of whether CYP3A inhibition is an intrinsic characteristic of P-gp inhibitors, a matter of concern in the development and rational use of such agents. Thus, the purpose of the present study was to determine whether the ability to inhibit P-gp and CYP3A is, in fact, linked and whether specific P-gp inhibitors with limited ability to inhibit CYP3A can be identified. Therefore, the potency of a series of 14 P-gp inhibitors was assessed by measuring their inhibition of the transepithelial flux across Caco-2 cells of digoxin, a prototypical P-gp substrate. CYP3A inhibition was determined from the impairment of nifedipine oxidation by human liver microsomes. Determination of the apparent K i values for CYP3A inhibition and the IC 50 s for P-gp and CYP3A inhibition allowed comparison of the relative inhibitory potency of the compounds on the two proteins’ function. The IC 50 s for P-gp inhibition ranged from 0.04 to 3.8 µ M . All compounds inhibited CYP3A with apparent K i values of between 0.3 and 76 µ M and IC 50 s between 1.5 and 50 µ M . However, no correlation was found between the extent of P-gp inhibition and CYP3A inhibition, and the ratio of the IC 50 for CYP3A inhibition to the IC 50 for P-gp inhibition varied from 1.1 to 125. These results demonstrate that, although many P-gp inhibitors are potent inhibitors of CYP3A, a varying degree of selectivity is present. The development and use of P-gp inhibitors with minimal or absent CYP3A inhibitory effects should decrease the impact of drug interactions on the therapeutic use of such compounds. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies

P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of Inhibitory Potencies

Cancer Research , Volume 59 (16): 3944 – Aug 1, 1999

Abstract

Many P-glycoprotein (P-gp) inhibitors studied in vitro and in vivo are also known or suspected to be substrates and/or inhibitors of cytochrome P-450 3A (CYP3A). Such overlap raises the question of whether CYP3A inhibition is an intrinsic characteristic of P-gp inhibitors, a matter of concern in the development and rational use of such agents. Thus, the purpose of the present study was to determine whether the ability to inhibit P-gp and CYP3A is, in fact, linked and whether specific P-gp inhibitors with limited ability to inhibit CYP3A can be identified. Therefore, the potency of a series of 14 P-gp inhibitors was assessed by measuring their inhibition of the transepithelial flux across Caco-2 cells of digoxin, a prototypical P-gp substrate. CYP3A inhibition was determined from the impairment of nifedipine oxidation by human liver microsomes. Determination of the apparent K i values for CYP3A inhibition and the IC 50 s for P-gp and CYP3A inhibition allowed comparison of the relative inhibitory potency of the compounds on the two proteins’ function. The IC 50 s for P-gp inhibition ranged from 0.04 to 3.8 µ M . All compounds inhibited CYP3A with apparent K i values of between 0.3 and 76 µ M and IC 50 s between 1.5 and 50 µ M . However, no correlation was found between the extent of P-gp inhibition and CYP3A inhibition, and the ratio of the IC 50 for CYP3A inhibition to the IC 50 for P-gp inhibition varied from 1.1 to 125. These results demonstrate that, although many P-gp inhibitors are potent inhibitors of CYP3A, a varying degree of selectivity is present. The development and use of P-gp inhibitors with minimal or absent CYP3A inhibitory effects should decrease the impact of drug interactions on the therapeutic use of such compounds.

Loading next page...
 
/lp/american-association-of-cancer-research/p-glycoprotein-and-cytochrome-p-450-3a-inhibition-dissociation-of-j4r0P2dT6i

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 1999 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

Many P-glycoprotein (P-gp) inhibitors studied in vitro and in vivo are also known or suspected to be substrates and/or inhibitors of cytochrome P-450 3A (CYP3A). Such overlap raises the question of whether CYP3A inhibition is an intrinsic characteristic of P-gp inhibitors, a matter of concern in the development and rational use of such agents. Thus, the purpose of the present study was to determine whether the ability to inhibit P-gp and CYP3A is, in fact, linked and whether specific P-gp inhibitors with limited ability to inhibit CYP3A can be identified. Therefore, the potency of a series of 14 P-gp inhibitors was assessed by measuring their inhibition of the transepithelial flux across Caco-2 cells of digoxin, a prototypical P-gp substrate. CYP3A inhibition was determined from the impairment of nifedipine oxidation by human liver microsomes. Determination of the apparent K i values for CYP3A inhibition and the IC 50 s for P-gp and CYP3A inhibition allowed comparison of the relative inhibitory potency of the compounds on the two proteins’ function. The IC 50 s for P-gp inhibition ranged from 0.04 to 3.8 µ M . All compounds inhibited CYP3A with apparent K i values of between 0.3 and 76 µ M and IC 50 s between 1.5 and 50 µ M . However, no correlation was found between the extent of P-gp inhibition and CYP3A inhibition, and the ratio of the IC 50 for CYP3A inhibition to the IC 50 for P-gp inhibition varied from 1.1 to 125. These results demonstrate that, although many P-gp inhibitors are potent inhibitors of CYP3A, a varying degree of selectivity is present. The development and use of P-gp inhibitors with minimal or absent CYP3A inhibitory effects should decrease the impact of drug interactions on the therapeutic use of such compounds.

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Aug 1, 1999

There are no references for this article.